Immuneering Co. (NASDAQ:IMRX) Receives $12.60 Consensus Target Price from Analysts

Immuneering Co. (NASDAQ:IMRX) has been given a consensus rating of “Moderate Buy” by the seven ratings firms that are presently covering the firm, MarketBeat.com reports. Three analysts have rated the stock with a hold recommendation and four have assigned a buy recommendation to the company. The average twelve-month target price among brokers that have issued ratings on the stock in the last year is $12.60.

A number of research firms recently issued reports on IMRX. Chardan Capital lowered their price target on Immuneering from $16.00 to $12.00 and set a “buy” rating on the stock in a report on Wednesday, August 7th. Needham & Company LLC reiterated a “buy” rating and issued a $15.00 target price on shares of Immuneering in a research note on Friday, September 13th.

Hedge Funds Weigh In On Immuneering

Hedge funds have recently bought and sold shares of the company. Marshall Wace LLP purchased a new position in shares of Immuneering in the second quarter valued at $492,000. Renaissance Technologies LLC acquired a new stake in Immuneering during the 2nd quarter valued at $447,000. Vanguard Group Inc. increased its position in Immuneering by 12.1% during the first quarter. Vanguard Group Inc. now owns 1,203,666 shares of the company’s stock worth $3,479,000 after buying an additional 129,851 shares in the last quarter. Acadian Asset Management LLC acquired a new position in shares of Immuneering in the second quarter worth $67,000. Finally, Point72 Asia Singapore Pte. Ltd. purchased a new stake in shares of Immuneering in the second quarter valued at $44,000. 67.65% of the stock is owned by hedge funds and other institutional investors.

Immuneering Stock Up 0.5 %

IMRX opened at $1.87 on Friday. The firm has a market cap of $55.45 million, a price-to-earnings ratio of -0.98 and a beta of -0.45. Immuneering has a 52 week low of $1.00 and a 52 week high of $8.89. The business’s 50 day moving average is $2.02 and its two-hundred day moving average is $1.59.

Immuneering (NASDAQ:IMRX) last announced its earnings results on Tuesday, August 6th. The company reported ($0.47) EPS for the quarter, beating analysts’ consensus estimates of ($0.52) by $0.05. Equities analysts expect that Immuneering will post -1.89 EPS for the current fiscal year.

Immuneering Company Profile

Immuneering Corporation, a clinical-stage oncology company, engages in the development of medicines for broad populations of cancer patients. Its lead product candidates include IMM-1-104, a dual-MEK inhibitor currently under Phase 1/2a clinical trial to treat patients with cancer, including pancreatic, melanoma, colorectal, and non-small cell lung cancer caused by mutations of RAS and/or RAF; and IMM-6-415 is in Investigational New Drug application to treat solid tumors.